Holen Sie sich die Stockscreener-App
2.75
2.48%
-0.07
Handel nachbörslich:
2.72
-0.03
-1.09%
Schlusskurs vom Vortag:
$2.82
Offen:
$2.79
24-Stunden-Volumen:
49,793
Relative Volume:
0.28
Marktkapitalisierung:
$93.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-16.77
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
+0.00%
1M Leistung:
+16.03%
6M Leistung:
+165.37%
1J Leistung:
+63.69%
1-Tages-Spanne:
$2.71
$2.8482
1-Wochen-Bereich:
$2.46
$3.10
52-Wochen-Spanne:
$0.8075
$3.11
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OKYO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.75 | 102.92M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma Limited Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What analysts say about OKYO Pharma Limited stockRapid-fire capital growth - jammulinksnews.com
Is OKYO Pharma Limited a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
What drives OKYO Pharma Limited stock priceHigh-profit capital plays - jammulinksnews.com
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa
OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener
OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia
OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener
OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks
OKYO posts trial data for lead drug in eye pain (OKYO:NASDAQ) - Seeking Alpha
OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain - Proactive financial news
Small cap wrap: OKYO Pharma, North Bay Resources, Nevis Brands, Nextech3D.ai... - Proactive financial news
OKYO Pharma Says Phase 2 Study of Urcosimod Showed 'Marked Reduction' in Neuropathic Corneal Pain Scores - MarketScreener
OKYO Pharma stock surges after positive Phase 2 results for eye pain drug - Investing.com Australia
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma reports positive top-line results from Phase 2 urcosimod trial - Investing.com Nigeria
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain - Proactive financial news
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
How FIGS Inc. stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
What makes OKYO Pharma Limited stock price move sharplyConsistent Growth Alert - Newser
How ArrowMark Financial Corp. stock performs during market volatilityFree Stock Market Courses - Newser
How OKYO Pharma Limited stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):